Escitalopram Oxalate is the oxalate salt form of escitalopram, a selective serotonin reuptake inhibitor utilized primarily in the treatment of major depressive disorder and generalized anxiety disorder. Produced via advanced asymmetric synthesis and stereoselective crystallization techniques, this active pharmaceutical ingredient exhibits high enantiomeric purity. It functions by inhibiting the neuronal reuptake of serotonin, thereby enhancing serotonergic neurotransmission in the central nervous system.
Product Information
|
Parameter |
Specification Details |
|
International Nonproprietary Name |
Escitalopram Oxalate |
|
Chemical Name |
(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile oxalate |
|
Therapeutic Category |
Antidepressant / Selective Serotonin Reuptake Inhibitor |
|
Grade |
Pharmaceutical Commercial Grade |
|
Physical Description |
White or almost white crystalline powder |
|
Solubility Profile |
Sparingly soluble in water; freely soluble in methanol; slightly soluble in ethanol |
Quality & Specification
|
Test Parameter |
Acceptance Criteria |
Analytical Method |
|
Assay (Dried Basis) |
98.0% - 102.0% |
High-Performance Liquid Chromatography |
|
Appearance of Solution |
Clear and colorless |
European Pharmacopoeia / United States Pharmacopeia |
|
Chiral Purity (R-enantiomer) |
≤ 0.1 % |
Chiral Liquid Chromatography |
|
Individual Specified Impurity |
≤ 0.10 % |
Liquid Chromatography |
|
Total Impurities |
≤ 0.5 % |
Liquid Chromatography |
|
Loss on Drying |
≤ 0.5 % |
Gravimetric Analysis |
|
Residue on Ignition |
≤ 0.1 % |
Sulfated Ash Test |
|
Heavy Metals |
≤ 10 ppm |
Inductively Coupled Plasma Mass Spectrometry |
Manufacturing & Supply
Synthesis Route: Asymmetric reduction followed by fractional crystallization to isolate the active S-enantiomer configuration.
Cleanroom Classification: Synthesis, isolation, and micronization executed within ISO Class 8 cleanroom environments.
Containment & Handling: Closed-system reactors equipped with automated nitrogen purging to prevent moisture absorption and cross-contamination.
Batch Scale & Capacity: Commercial-scale production capabilities ranging from multi-hundred-kilogram to metric-ton annual output.
Supply Stability: Maintained safety stock of key starting materials and validated dual-sourcing channels for critical raw components.
Documentation
Regulatory Dossiers: Drug Master File available for reference and active European Pharmacopoeia compliance data.
Certificates of Analysis: Issued for every individual production batch, detailing full analytical results against pharmacopoeial monographs.
Compliance Certificates: Good Manufacturing Practice certificates and Written Confirmation for active substances imported into regulated markets.
Supporting Data: Full impurity profiling reports, residual solvent validation data, stability study summaries, and TSE/BSE-free statements.
Packaging
|
Primary Packaging |
Double-layer food-grade low-density polyethylene bags, heat-sealed to ensure absolute moisture and light protection. |
|
Secondary Packaging |
Rigid fiber drums or rigid high-density polyethylene drums lined with tamper-evident seals. |
|
Standard Batch Packaging Size |
25 kg net weight per drum. |
|
Storage Conditions |
Store below 25°C in a dry, well-ventilated area protected from direct sunlight and moisture. |
Pharmaceutical Application
Major Depressive Disorder: Formulated into oral tablets and liquid solutions to manage acute and maintenance phases of clinical depression. Restores neurochemical balance by sustaining extracellular serotonin levels in synaptic clefts.
Generalized Anxiety Disorder: Utilized in solid oral dosage manufacturing for chronic anxiety management. Regulates emotional and somatic symptoms through continuous central nervous system modulation.
Social Anxiety Disorder: Applied in specialized tablet formulations targeting chronic social fear and avoidance behaviors. Supports long-term psychiatric rehabilitation protocols.
Panic Disorder: Integrated into precise dose-strength tablets designed to reduce the frequency and intensity of unexpected panic attacks. Stabilizes autonomic nervous system responses over therapeutic treatment cycles.
FAQ
Q: What is the standard minimum order quantity for commercial orders?
A: The standard minimum order quantity for commercial batches is 25 kg, with pilot-scale sample quantities available upon request for technical evaluation.
Q: Is a Drug Master File available for regulatory submissions?
A: Yes, a comprehensive Drug Master File is maintained and available for submission to regulatory authorities to support customer regulatory filings.
Q: How is chiral purity verified during production?
A: Chiral purity is monitored using validated high-performance liquid chromatography methods with chiral stationary phases to ensure the R-enantiomer remains below established pharmacopoeial thresholds.
Q: What are the recommended storage and handling conditions?
A: The material should be stored in original sealed containers below 25°C, protected from humidity, strong light, and atmospheric oxidation.
Q: Are reference analytical standards provided with the shipment?
A: Working analytical standards and comprehensive impurity reference markers can be supplied alongside commercial batches upon technical request.
Hot Tags: escitalopram oxalate, China escitalopram oxalate manufacturers, suppliers, factory





